Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: A Spanish expanded access trial
Entity
UAM. Departamento de Medicina; Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)Publisher
BioMed CentralDate
2016-09-26Citation
10.1186/s13023-016-0517-9
Orphanet Journal of Rare Diseases 11.1 (2016): 128
ISSN
1750-1172DOI
10.1186/s13023-016-0517-9Funded by
This work was funded by Novartis Farmacéutica S.A., which was involved in study design, data analysis and interpretation, and writing of the manuscriptEditor's Version
http://dx.doi.org/10.1186/s13023-016-0517-9Subjects
Angiomyolipoma; Everolimus; Safety; Tuberous sclerosis complex; MedicinaRights
© 2016 The Author(s)Abstract
Background: Renal angiomyolipomas (AML) are usual manifestations of tuberous sclerosis complex (TSC) that may cause aneurism-related haemorrhages and renal impairment. Everolimus has emerged as an alternative to surgery/embolization. We provide further insight into everolimus safety and efficacy for TSC-related AML. Methods: This was a Spanish expanded access trial including patients aged ≥18 years with TSC-related AML. They received 10 mg everolimus once daily until AML progression, unacceptable toxicity, death/withdrawal, commercialisation for TSC-related AML, or 1 year after first patient enrolment. The primary outcome was dose-limiting safety according to grade 3/4 adverse events, serious adverse events, or adverse events leading to treatment modification. Secondary outcomes included overall safety and efficacy. Results: Nineteen patients were enrolled and received everolimus for a median of 6.6 (5.3-10.9) months. Eleven (57.9 %) remained on 10 mg/day throughout the study and eight (42.1 %) required treatment modifications due to adverse events; none permanently discontinued treatment. Adverse events were overall grade 1/2 and most frequently included aphthous stomatitis/mucosal inflammation, hypercholesterolaemia/hypertriglyceridaemia, urinary tract infection, hypertension, dermatitis acneiform, and insomnia. Four (21.1 %) patients experienced grade 3 adverse events, none was grade 4, and only one (5.3 %) was serious (pneumonia). AML volume was reduced ≥30 % in 11 (57.9 %) patients and ≥50 % in 9 (47.4 %); none progressed. Right and left kidney sizes decreased in 16 and 14 patients, respectively. Conclusions: These findings support the benefit of everolimus for renal AML due to a manageable safety profile accompanied by reduced AML and kidney volumes. Trial registration: EudraCT number 2012-005397-63; date of registration 22 Nov 2012.
Files in this item
Google Scholar:Robles, Nicolás Roberto
-
Peces, Ramón
-
Gómez-Ferrer, Álvaro
-
Villacampa, Felipe
-
Álvarez-Ossorio, Jose Luis
-
Pérez-Segura, Pedro
-
Morote, Juan
-
Herrera-Imbroda, Bernardo
-
Nieto, Javier
-
Carballido Rodríguez, Joaquín
-
Anido, Urbano
-
Valero, Marian
-
Meseguer, Cristina
-
Torra, Roser
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
Alcaraz, A.; González-López, Raquel; Morote, J.; De La Piedra, Concepción; Meseguer, Cristina; Esteban, Emilio; Climent, Miguel Ángel; González-Gragera, B.; Álvarez-Ossorio, Jose Luis; Chirivella, Isabel; Mellado, Begoña; Lara, Pedro Carlos; Vázquez, Fernando Javier; Contreras Viedma, José Antonio; Carles, Joan; Murias, Adolfo; Calderero, Verónica; Comet-Batlle, Josep; González Del Alba, Aránzazu; León Mateos, Luis A.; Mañas, Ana; Segarra, José; Lassa, A.; González Enguita, María del Carmen; Méndez, Míriam J.; Samper, Pilar María; Unda, Miguel; Mahillo, Ignacio; Bellmunt, Joaquim; Alcaraz, A.; González-López, Raquel; Morote, J.; De La Piedra, Concepción; Meseguer, Cristina; Esteban, Emilio; Climent, Miguel Ángel; González-Gragera, B.; Álvarez-Ossorio, Jose Luis; Chirivella, Isabel; Mellado, Begoña; Lara, Pedro Carlos; Vázquez, Fernando Javier; Contreras, José Antonio Viedma; Carles, Joan; Murias, Adolfo; Calderero, Verónica; Comet-Batlle, Josep; González Del Alba, Aránzazu; León Mateos, Luis A.; Mañas, Ana; Segarra, José; Lassa, A.; González Enguita, María del Carmen
; Méndez, Míriam J.; Samper, Pilar María; Unda, Miguel; Mahillo, Ignacio; Bellmunt, Joaquim
2013-07-09 -
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
De La Piedra, Concepción; Alcaraz, A.; Bellmunt, Joaquim; Meseguer, Cristina; Gómez Caamaño, Antonio; Ribal, María José; Vázquez, Fernando Javier; Anido, Urbano; Samper, Pilar María; Esteban, Emilio; Álvarez-Ossorio, Jose Luis; Lara, Pedro Carlos; San José, L. A.; Contreras, José Antonio Viedma; Del Alba, Aránzazu González; González-Gragera, B.; Tabernero, Ángel J.; González Enguita, María del Carmen; Fernández, Jesús María; García-Escudero, Antonio; Gómez-Veiga, Francisco J.; Méndez, Míriam J.; Segarra, José; Virizuela, Juan Antonio; Carles, Joan; Lassa, A.; Calderero, Verónica; Constela, Manuel; Delgado, Diego Hernán; Mañas, Ana; Murias, Adolfo; Reynés, Gaspar; Rodríguez, Begoña I.; Rubio, Gustavo; Sánchez, Ernesto Sánchez; Unda, Miguel; Solsona, Eduardo; Martínez Javaloyas, J. M.; Comet-Batlle, Josep; Quicios, C.; Martín-Fernández, Marta; Mahillo, Ignacio; Moróte, Juan Moróte
2013-06-25 -
Clinical efficacy and safety of fanhdi<sup>®</sup>, a plasma-derived VWF/Factor VIII concentrate, in von willebrand disease in Spain: a retrospective study
Jiménez Yuste, Víctor Manuel; Álvarez Roman, María Teresa
; Palomo Bravo, Ángeles; Galmes, Bernardo J.; Nieto Hernández, Maria del Mar; Benítez Hidalgo, Olga; Marzo Alonso, Cristina; Pérez González, Noelia Florencia; Coll, Julia; Núñez, Ramiro; Carrasco, Marina; García Candel, Faustino; Gonzalez-Porras, Jose Ramon; Hernández García, Carmen; Varó Castro, Maria José; Mir, Roser
2022-01-02